Trials / Unknown
UnknownNCT05883670
Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer
Evaluate Efficacy and Safety of Serplulimab（HLX10）in Patients With Advanced, Recurrent and Metastatic Cervical Cancer：A Prospective, Multicenter, Non-interventive Real-world Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 118 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Prospective, Multicenter, non-interventive Real-world Study to evaluate the efficacy and safety of the treatment of Serplulimab in patients with Advanced,Recurrent and Metastatic Cervical Cancer. Approximately 118 eligible subjects are planned to be enrolled across all sites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Serplulimab | Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. |
Timeline
- Start date
- 2023-03-09
- Primary completion
- 2024-03-31
- Completion
- 2025-12-31
- First posted
- 2023-06-01
- Last updated
- 2023-06-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05883670. Inclusion in this directory is not an endorsement.